Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
72,922,597
-
Total 13F shares
-
29,735,114
-
Share change
-
+1,722,736
-
Total reported value
-
$268,784,196
-
Price per share
-
$9.04
-
Number of holders
-
67
-
Value change
-
+$10,322,369
-
Number of buys
-
48
-
Number of sells
-
13
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q3 2024
As of 30 Sep 2024,
Lexeo Therapeutics, Inc. - Common Stock (LXEO) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,735,114 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., D1 Capital Partners L.P., Omega Fund Management, LLC, EVENTIDE ASSET MANAGEMENT, LLC, BlackRock, Inc., Frazier Life Sciences Management, L.P., Blackstone Inc., and Novo Holdings A/S.
This page lists
67
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.